EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Molecular Diagnostics‐Guided Immunosuppression Minimization to Belatacept Monotherapy in Kidney Transplant Recipients

Juan D. Salcedo‐Betancourt, Cyrus Feizpour, Morgan Marsh, Hwarang S. Han, Laila Lakhani, Swee‐Ling Levea, Lee Anderson, David Wojciechowski

Clinical Transplantation · 2026-11 · 40 (11)

DOI: 10.1111/ctr.70772 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2026-11-21. Written by Juan D. Salcedo‐Betancourt and 7 co-authors. 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CareDx.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Minimally invasive molecular diagnostics, including donor‐derived cell‐free DNA (dd‐cfDNA) and gene expression profiling, reliably distinguish immune quiescence from allograft injury; however, their utility in guiding immunosuppression minimization has not been fully evaluated.

Methods

We conducted a 12‐month prospective, single‐arm observational proof of concept study to determine whether integration of dd‐cfDNA (AlloSure), gene expression profiling (AlloMap), and conventional clinical biomarkers could facilitate immunosuppression reduction toward belatacept monotherapy in kidney transplant recipients. Adult recipients ≥9 months post‐transplant receiving belatacept‐based immunosuppression with stable renal function (eGFR >40 mL/min/1.73 m 2 ), AlloSure ≤1%, and no donor‐specific antibodies were enrolled. A three‐month lead‐in period confirmed immune quiescence prior to stepwise immunosuppression reduction.

Results

Of 25 consented participants, 23 completed the lead‐in period. Median dd‐cfDNA remained

Funding

  • CareDx

Cite

APA

Salcedo‐Betancourt, J. D., Feizpour, C., Marsh, M., Han, H. S., Lakhani, L., Levea, S., Anderson, L., & Wojciechowski, D. (2026). Molecular Diagnostics‐Guided Immunosuppression Minimization to Belatacept Monotherapy in Kidney Transplant Recipients. Clinical Transplantation, 40(11). https://doi.org/10.1111/ctr.70772

Vancouver

Salcedo‐Betancourt JD, Feizpour C, Marsh M, Han HS, Lakhani L, Levea S, et al. Molecular Diagnostics‐Guided Immunosuppression Minimization to Belatacept Monotherapy in Kidney Transplant Recipients. Clinical Transplantation. 2026;40(11). doi:10.1111/ctr.70772

BibTeX
@article{SalcedoBetancourt2026,
  author = {Salcedo‐Betancourt, Juan D. and Feizpour, Cyrus and Marsh, Morgan and Han, Hwarang S. and Lakhani, Laila and Levea, Swee‐Ling and Anderson, Lee and Wojciechowski, David},
  title = {Molecular Diagnostics‐Guided Immunosuppression Minimization to Belatacept Monotherapy in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {11},
  doi = {10.1111/ctr.70772}
}
Start for free →